Ipamorelin vs MK-677
Ipamorelin and MK-677 both stimulate growth hormone release through ghrelin-related pathways, but with important differences in selectivity and side effect profiles. Ipamorelin is a true peptide requiring injection, while MK-677 is a non-peptide small molecule taken orally.
Side-by-Side Comparison
| Category | Ipamorelin | MK-677 |
|---|---|---|
| Mechanism of action | Selective growth hormone secretagogue that activates GHS-R1a receptors on the pituitary. Triggers GH pulses without significantly raising cortisol, prolactin, or stimulating appetite. | Non-peptide ghrelin mimetic that activates the same GHS-R1a receptors but less selectively. Increases GH, IGF-1, appetite, and can modestly raise cortisol and prolactin. |
| Primary research area | Clean GH release for body composition and recovery. Valued for selectivity — minimal impact on other hormones. | GH deficiency, muscle wasting, bone density, sleep quality. The most studied oral GH secretagogue. |
| Evidence level | Phase II clinical trials. Published human data confirming selective GH release. Not FDA-approved. | Multiple human clinical trials including a 2-year study (Nass et al., 2008). More published human data than Ipamorelin. Not FDA-approved. |
| Administration route | Subcutaneous injection, 1-3 times daily. | Oral (capsule or liquid), once daily. |
| Typical research dosing | 100-300 mcg subcutaneous, 1-3x daily. Often before bed. | 10-25 mg orally once daily, typically before bed. |
| Key studies/evidence | Raun et al. (1998) — selectivity studies. Human trials showing GH release without cortisol/prolactin elevation. Phase II data. | Nass et al. (2008) — 2-year human study. Murphy et al. (1998) — body composition. More extensive published human trial data. |
Can They Be Stacked?
Can be combined since both act on ghrelin receptors but may provide slightly different activation patterns. However, most practitioners choose one or the other rather than stacking two ghrelin-pathway compounds. A more synergistic approach would pair either one with a GHRH analog (like CJC-1295) to activate the complementary pathway.
Verdict
MK-677 wins on convenience (oral) and depth of human evidence (2-year study). Ipamorelin wins on selectivity — it raises GH without significantly affecting cortisol, prolactin, or appetite. For those concerned about appetite stimulation, water retention, or hormonal side effects, Ipamorelin is the cleaner option. For those who want oral dosing and the most studied GH secretagogue, MK-677 is the practical choice.
Related Comparisons
CJC-1295 and Ipamorelin are both growth hormone secretagogues, but they work through different receptor pathways. CJC-1295 is a GHRH (growth hormone-releasing hormone) analog, while Ipamorelin is a growth hormone-releasing peptide (GHRP). They are frequently combined rather than used as alternatives.
MK-677 vs CJC-1295MK-677 (Ibutamoren) and CJC-1295 both elevate growth hormone levels, but through entirely different mechanisms and routes. MK-677 is technically not a peptide -- it's a non-peptide ghrelin mimetic taken orally. CJC-1295 is a GHRH analog that requires injection. This distinction significantly affects their use profiles.
Disclaimer: This content is for educational purposes only and does not constitute medical advice. Peptides are biologically active compounds that carry risks. Consult a healthcare provider before using any peptides. Many peptides discussed here have limited human clinical data — always verify current research status before making decisions.